Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alofanib - Russian Pharmaceutical Technologies

Next Previous
Drug Profile

Alofanib - Russian Pharmaceutical Technologies

Alternative Names: RPT-835

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Russian Pharmaceutical Technologies
  • Class Antineoplastics; Benzoic acids; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastric cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Second-line therapy or greater) in Russia (IV)
  • 18 Sep 2025 Discontinued - Preclinical for Breast cancer in Russia (PO) (Russian Pharmaceutical Technologies pipeline, September 2025)
  • 18 Sep 2025 Discontinued - Preclinical for Ovarian cancer in Russia (IV) (Russian Pharmaceutical Technologies pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top